Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: Effect of gender, smoking and APOE genotypes

Clinica Chimica Acta

Volumn 380, Issue 1-2, 2007, Pages 175-181

  Fiegenbaum, Marilu ^a,b   de Andrade, Fabiana Michelsen ^a,c   Hutz, Mara H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b CENTRO UNIVERSITÁRIO METODISTA IPA   (Brazil)

^c UNIVERSIDADE FEEVALE   (Brazil)

Author keywords

APOC3 polymorphisms; APOE; Gender; Smoking; Triglycerides

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; ESTROGEN; GENOMIC DNA; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANALYZER; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BRAZIL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COLORIMETRY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DNA SEQUENCE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS E; BRAZIL; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; GENOTYPE; HUMANS; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SEX FACTORS; SMOKING; TRIGLYCERIDES; VARIATION (GENETICS);

EID: 33947642520     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.02.007     Document Type: Article

References (49)

1. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 (1998) 7B-12B
2. Brewer H.B. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 83 (1999) 3F-12F
3. Wang C.S., McConathy W.J., Kloer H.U., and Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75 (1985) 384-390
4. Fredenrich A. Role of apolipoprotein CIII in triglyceride-rich lipoprotein metabolism. Diabetes Metab 23 (1998) 490-495
5. Shachter N.S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12 (2001) 297-304
6. Dallongeville J., Meirhaeghe A., Cottel D., Fruchart J.-C., Amoyel P., and Helbecque N. Gender related association between genetic variations of APOC3 gene and lipid and lipoprotein variables in northern France. Atherosclerosis 150 (2000) 149-157
7. Corella D., Guillen M., Saiz C., et al. Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus. J Lipid Res 43 (2002) 416-427
8. Surguchov A.P., Page G.P., Smith L., Patsch W., and Boerwinkle E. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 16 (1996) 941-947
9. Dammerman M., Sandkuijl L.A., Halaas J.L., Chung W., and Breslow J.L. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′untranslated region polymorphisms. Proc Natl Acad Sci U S A 90 (1993) 4562-4566
10. Russo G.T., Meigs J.B., Cupples L.A., et al. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid concentrations, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis 158 (2001) 173-181
11. Waterworth D.M., Talmud P.J., Bujac S.R., Fisher R.M., Miller G.J., and Humphries S.E. Contribution of apolipoprotein C-III gene variants to determination of triglyceride concentrations and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol 20 (2000) 2663-2669
12. Shoulders C.C., Grantham T.T., North J.D., et al. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Hum Genet 98 (1996) 557-566
13. Dallinga-Thie G.M., Bu X.D., van Linde-Sibenius Trip M., et al. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 37 (1996) 136-147
14. Olivieri O., Stranieri C., Bassi A., et al. ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res 43 (2002) 1450-1457
15. Islam S., Raitakari O.T., Juonala M., et al. Apolipoprotein A-I/C-III/A-IV SstI and apolipoprotein B XbaI polymorphisms and their association with carotid artery intima-media thickness in the Finnish population. The cardiovascular risk in young Finns study. Atherosclerosis 180 (2005) 79-86
16. Waterworth D.M., Hubacek J.A., Kovar J., Poledne R., Humprhies S.E., and Talmud P.H. Plasma concentrations of remnant particles are determined in part by variation in the APOC3 gene insulin response element and the APOCI-APOE cluster. J Lipid Res 41 (2000) 1103-1109
17. Hegele R.A., Connelly P.W., Hanley A.J.G., Sun F., Harris S.B., and Zinman B. Common genomic variation in the apoC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol 17 (1997) 2753-2758
18. Dallongeville J., Meirhaeghe A., Cottel D., Fruchart J.-C., Amoyel P., and Helbecque N. Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides or triglyceride-rich lipoproteins in humans. Int J Obes Relat Metab Disord 25 (2001) 1012-1017
19. Hubacek J.A., Waterworth D.M., Poledne R., et al. Genetic determination of plasma lipid and insulin in the Czech population. Clin Biochem 34 (2001) 113-118
20. Waterworth D.M., Talmud P.J., Humphries S.E., et al. Variable effect of the APOC3 -482C>T variant on insulin, glucose and triglyceride concentrations in different ethnic groups. Diabetologia 44 (2001) 245-248
21. Groenendijk M., Cantor R.M., Blom N.H.H.C., Rotter J.I., De Bruin T.W.A., and Dallinga-Thie G.M. Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia. J Lipid Res 40 (1999) 1036-1044
22. Dallinga-Thie G.M., Groenendijk M., Blom R.N.H.H., De Bruin T.W.A., and De Kant E. Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin. J Lipid Res 42 (2001) 1450-1456
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
24. Friedewald N.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
25. World Health Organization. Obesity: preventing and managing the global epidemic (1988), World Health Organization, Geneva Report of a WHO consultation on obesity, Geneva, 3-5 June 1997
26. Lahiri D.K., and Nurnberger J.I. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19 (1991) 5444
27. Oppert J.M., Fumeron F., Moreel J.F., and Apfelbaum M. Association of a DNA polymorphism of the apolipoprotein A-I/C-III/A-IV gene cluster with hypertriglyceridemia in obese people. Int J Obes Relat Metab Disord 16 (2002) 891-896
28. Maekawa B., Cole T.G., Seip R.L., and Bylund D. Apolipoprotein E genotyping methods for the clinical laboratory. J Clin Lab Anal 9 (1995) 63-69
29. Schneider S., Roessli D., and Excoffier L. Arlequin ver. 2.000. A software for population genetics data analysis (2000), University of Geneva, Geneva
30. Lewontin R.C. On measures of gametic disequilibrium. Genetics 120 (1988) 849-852
31. de Andrade F.M., Larrandaburu M., Callegari-Jacques S.M., Gastaldo G., and Hutz M.H. Association of apolipoprotein E polymorphism with plasma lipids and Alzheimer's disease in a southern Brazilian population. Braz J Med Biol Res 33 (2000) 529-537
32. Aalto-Setala K., Fisher E.A., Chen X., et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 90 (1992) 1889-1900
33. Aalto-Setala K., Weinstock P.H., Bisgaier C.L., Wu L., Smith J.D., and Breslow J.L. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res 37 (1996) 1802-1811
34. de Silva H.V., Lauer S.J., Wang J., et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 269 (1994) 2324-2335
35. Tarr P.E., Taffé P., Bleiber G., et al. Modeling the influence of APOC3, APOE and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 191 (2005) 1419-1427
36. Pedersen J.C., and Berg K. Gene-gene interaction between the low-density lipoprotein receptor and apolipoprotein E loci affects lipid concentrations. Clin Genet 38 (1990) 287-294
37. Mahley R.W., and Rall Jr. S.C. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1 (2000) 507-537
38. St-Amand J., Moorjanit S., Lupien P.J., Prud'homme D., and Despres J.P. The relation of plasma triglyceride, apolipoprotein B, and high-density lipoprotein cholesterol to postheparin lipoprotein lipase activity is dependent on apolipoprotien E polymorphism. Metabolism 45 (1996) 261-267
39. Waterworth D.M., Talmud P.J., Luan J., et al. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochim Biophys Acta 1637 (2003) 200-206
40. Deeb S.S., Zambon A., Carr M.C., Ayyobi A.F., and Brunzell J.D. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res 44 (2003) 1279-1286
41. Hellerstein M.K., Benowitz N.L., Neese R.A., et al. Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J Clin Invest 93 (1994) 265-272
42. Stephens J.W., and Humphries S.E. The molecular genetics of cardiovascular disease: clinical implications. J Intern Med 253 (2003) 120-127
43. Eliasson B., Mero N., Taskinen M.R., and Smith U. The insulin resistance syndrome and postprandial lipid intolerance in smokers. Atherosclerosis 129 (1997) 79-88
44. Groenendijk M., Cantor R.M., de Bruin T.W.A., and Dallinga-Thie G.M. The apoAI-CIII-AIV gene cluster. Atherosclerosis 157 (2001) 1-11
45. Hoffer M.J., Sijbrands E.J., De Man F.H., Havekes L.M., Smelt A.H., and Frants R.R. Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. Eur J Clin Invest 28 (1998) 807-812
46. Seda O., and Sedova L. New apolipoprotein A-V: comparative genomics meets metabolism. Physiol Res 52 (2003) 141-146
47. Talmud P.J., Hawe E., Martin S., et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 11 (2002) 3039-3046
48. Olivier M., Wang X., Cole R., et al. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 83 (2004) 912-923
49. van Dijk K.W., Rensen P.C.N., Voshol P.J., and Havekes L.M. The role and mode of action of apolipoprotein CIII and AV: synergistic actors in triglyceride metabolism?. Curr Opin Lipidol 15 (2005) 239-246